Dr. Reddy's Laboratories announced the launch of carmustine for Injection, USP, a therapeutic equivalent generic version of BiCNU (carmustine for injection) approved by the U.S. Food and Drug Administration (USFDA).

The BiCNU brand and generic market had U.S. sales of approximately US $ 19.4 million MAT for the most recent twelve months ending in August 2021 according to IQVIA Health.

Dr. Reddy's carmustine for Injection, USP is a lyophilized powder available as a package. It includes a single-dose vial containing 100 mg carmustine USP and a vial containing a 3 mL sterile diluent.